Mar. 24 at 5:11 PM
$CDXS Author: Pierre Barratt, VP, Technical Client Services
How would you describe the mood of the outsourcing market right now – stabilising, cautious, or entering a new growth cycle?
Off the back of JPM 2026, the word on the proverbial street seems like the market is moving back into a new growth cycle. There is a positive sentiment but this time it is measured.
The client conversations that I’m in almost every day are fewer speculative proof of concepts and more conversations that assume the oligonucleotide asset has the opportunity to be manufactured at large scale. Funding is there, but drug innovators are performing thorough due diligence about where they place work and who they partner with. That’s especially true for anything innovative or capital-intensive. Early-stage demand is still developing, but the tone has shifted from “wait and see” to “let’s get ready when we succeed.”
https://247biopharma.com/article/25081/
